Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q7RTY9
UPID:
PRS41_HUMAN
Alternative names:
Testis serine protease 1
Alternative UPACC:
Q7RTY9
Background:
Serine protease 41, also known as Testis serine protease 1, encoded by the gene with accession number Q7RTY9, plays a crucial role in various biological processes. Its unique enzymatic activity, characterized by the cleavage of peptide bonds in proteins, positions it as a key player in physiological pathways, including digestion, immune response, and blood coagulation.
Therapeutic significance:
Understanding the role of Serine protease 41 could open doors to potential therapeutic strategies. Its involvement in critical physiological processes suggests that modulating its activity could offer new avenues for treating diseases where these pathways are dysregulated.